NICE's Rejection Of Takeda's Mepact In Osteosarcoma Causes Storm Of Protest
This article was originally published in PharmAsia News
Executive Summary
LONDON - Feelings are running high over NICE's initial rejection of the use of Takeda's osteosarcoma therapy, Mepact (mifamurtide), in the U.K. National Health Service
You may also be interested in...
Millennium Prospers Under Takeda--But Will Takeda Get Full Value?
In losing its autonomy as an independently traded entity, Millennium has finally gained the freedom to become a larger player in the oncology space. One year after being acquired by Takeda, the biotech must no longer demonstrate to Wall Street regular quarterly earnings from Velcade, its only product, while trying to fund additional trials and build its pipeline. The success of this new business model fashioned by Takeda for its acquisition is still an open question, but it could provide a winning formula for Big Pharma companies in dire need of rejuvenated pipelines.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).